Iqvia Holdings Inc. (IQV): Revenue
$16.31B
Year ended 2025-12-31
$16.63B
Trailing 12 months to 2026-03-31
+4.2%
3-year compound annual growth
+7.5%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.31B | +5.9% | 2026-02-17, From 2025-01-01 |
| 2024-12-31 | $15.40B | +2.8% | 2026-02-17, From 2024-01-01 |
| 2023-12-31 | $14.98B | +4.0% | 2026-02-17, From 2023-01-01 |
| 2022-12-31 | $14.41B | +3.9% | 2025-02-13, From 2022-01-01 |
| 2021-12-31 | $13.87B | +22.1% | 2024-02-15, From 2021-01-01 |
| 2020-12-31 | $11.36B | +2.4% | 2023-02-15, From 2020-01-01 |
| 2019-12-31 | $11.09B | +6.5% | 2022-02-16, From 2019-01-01 |
| 2018-12-31 | $10.41B | +7.3% | 2021-02-12, From 2018-01-01 |
| 2017-12-31 | $9.70B | +42.4% | 2020-02-18, From 2017-01-01 |
| 2016-12-31 | $6.82B | n/a | 2019-02-19, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $16.31B | +5.9% |
| Icon PLC (ICLR) | 2025-12-31 | $8.25B | +0.8% |
| Incyte Corp (INCY) | 2025-12-31 | $5.14B | +21.2% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $4.02B | -0.9% |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $2.53B | +20.0% |
| NRC Health (NRC) | 2025-12-31 | $137.39M | -4.0% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $33.03M | -14.5% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $18.67M | -29.3% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $16.37M | +304.0% |
Compare IQV, ICLR, INCY, CRL side by side · Screen every company in Services-Commercial Physical & Biological Research ↗